• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BioNexus Gene Lab Corp

    10/17/23 11:46:33 AM ET
    $BGLC
    Medical Specialities
    Health Care
    Get the next $BGLC alert in real time by email
    SC 13G 1 bglc_sc13g.htm SC 13G bglc_sc13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    BioNexus Gene Lab Corp.

    (Name of Issuer)

    Common Stock, no par value

    (Title of Class of Securities)

    090628207

    (CUSIP Number)

    July 19, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐     Rule 13d-1(b)

     

     

     

    ☐     Rule 13d-1(c)

     

     

     

    ☒     Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     SCHEDULE 13G

     

    CUSIP No. 090628207

     

     

    1

    Names of Reporting Persons

     

    Chan Chong Wong

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐

    (b)  ☐

    3

    Sec Use Only

     

     

    4

    Citizenship or Place of Organization

     

    Malaysia

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5

    Sole Voting Power

     

    1,031,427

    6

    Shared Voting Power

     

     

    7

    Sole Dispositive Power

     

    1,031,427

    8

    Shared Dispositive Power

     

     

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    5.80%1

    12

    Type of Reporting Person (See Instructions)

     

    IN

    ____________  

    1.

    On July 19, 2023 the reporting person was a beneficial owner of 7.19% of the Issuer’s issued and outstanding shares of common stock. As of October 4, 2023 the reporting person has a beneficial ownership of 5.80% based on the shares of common stock outstanding as reported by the Issuer’s transfer agent.

     

     
    2

     

      

    SCHEDULE 13G

     

    CUSIP No. 090628207

     

     

    1

    Names of Reporting Persons

     

    Chi Yuen Leong

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐

    (b)  ☐

    3

    Sec Use Only

     

     

    4

    Citizenship or Place of Organization

     

    Malaysia

      

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5

    Sole Voting Power

     

    1,166,673

    6

    Shared Voting Power

     

     

    7

    Sole Dispositive Power

     

    1,166,673

    8

    Shared Dispositive Power

     

     

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    6.56%2

    12

    Type of Reporting Person (See Instructions)

     

    IN

    ____________ 

    2.

    On July 19, 2023 the reporting person was a beneficial owner of 8.06% of the Issuer’s issued and outstanding shares of common stock. As of October 4, 2023 the reporting person has a beneficial ownership of 6.56% based on the shares of common stock outstanding as reported by the Issuer’s transfer agent.

     

     
    3

     

      

    SCHEDULE 13G

     

    CUSIP No. 090628207

     

     

    1

    Names of Reporting Persons

     

    Wong Kim Hai

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐

    (b)  ☐

    3

    Sec Use Only

     

     

    4

    Citizenship or Place of Organization

     

    Malaysia

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5

    Sole Voting Power

     

    900,872

    6

    Shared Voting Power

     

     

    7

    Sole Dispositive Power

     

    900,872

    8

    Shared Dispositive Power

     

     

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    5.06%3

    12

    Type of Reporting Person (See Instructions)

     

    IN

    ____________ 

    3.

    On July 19, 2023 the reporting person was a beneficial owner of 7.20% of the Issuer’s issued and outstanding shares of common stock. As of October 4, 2023 the reporting person has a beneficial ownership of 5.06% based on the shares of common stock outstanding as reported by the Issuer’s transfer agent.

     

     
    4

     

      

    SCHEDULE 13G

     

    CUSIP No. 090628207

     

     

    1

    Names of Reporting Persons

     

    Soo Kow Lai

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐

    (b)  ☐

    3

    Sec Use Only

     

     

    4

    Citizenship or Place of Organization

     

     

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5

    Sole Voting Power

     

    1,250,001

    6

    Shared Voting Power

     

     

    7

    Sole Dispositive Power

     

    1,250,001

    8

    Shared Dispositive Power

     

     

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    7.03%4

    12

    Type of Reporting Person (See Instructions)

     

    IN

    ____________ 

    4.

    On July 19, 2023 the reporting person was a beneficial owner of 8.63% of the Issuer’s issued and outstanding shares of common stock. As of October 4, 2023 the reporting person has a beneficial ownership of 7.03% based on the shares of common stock outstanding as reported by the Issuer’s transfer agent.

     

     
    5

     

      

    SCHEDULE 13G

     

    CUSIP No. 090628207

     

     

    1

    Names of Reporting Persons

     

    Tai Tan Liong

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐

    (b)  ☐

    3

    Sec Use Only

     

     

    4

    Citizenship or Place of Organization

     

     

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5

    Sole Voting Power

     

    1,041,706

    6

    Shared Voting Power

     

     

    7

    Sole Dispositive Power

     

    1,041,706

    8

    Shared Dispositive Power

     

     

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    5.85%5

    12

    Type of Reporting Person (See Instructions)

     

    IN

    ____________  

    5.

    On July 19, 2023 the reporting person was a beneficial owner of 7.20% of the Issuer’s issued and outstanding shares of common stock. As of October 4, 2023 the reporting person has a beneficial ownership of 5.85% based on the shares of common stock outstanding as reported by the Issuer’s transfer agent.

     

     
    6

     

      

    SCHEDULE 13G

     

    CUSIP No. 090628207

     

     

    1

    Names of Reporting Persons

     

    Tham Too Kam

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐

    (b)  ☐

    3

    Sec Use Only

     

     

    4

    Citizenship or Place of Organization

     

    Malaysia

      

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5

    Sole Voting Power

     

    875,872

    6

    Shared Voting Power

     

     

    7

    Sole Dispositive Power

     

    875,872

    8

    Shared Dispositive Power

     

     

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    4.92%6

    12

    Type of Reporting Person (See Instructions)

     

    IN

    ____________  

    6.

    On July 19, 2023 the reporting person was a beneficial owner of 7.03% of the Issuer’s issued and outstanding shares of common stock. As of October 4, 2023, the reporting person has a beneficial ownership of less than 5% based on the shares outstanding as reported by the Issuer’s transfer agent.

     

     
    7

     

      

     SCHEDULE 13G

     

    CUSIP No. 090628207

     

     

    1

    Names of Reporting Persons

     

    Tan Kuan Yew

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  ☐

    (b)  ☐

    3

    Sec Use Only

     

     

    4

    Citizenship or Place of Organization

     

    Malaysia

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5

    Sole Voting Power

     

    594,243

    6

    Shared Voting Power

     

     

    7

    Sole Dispositive Power

     

    594,243

    8

    Shared Dispositive Power

     

     

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ☐

    11

    Percent of class represented by amount in row (9)

     

    3.34%7

    12

    Type of Reporting Person (See Instructions)

     

    IN

    ____________ 

    7.

    On July 19, 2023 the reporting person was a beneficial owner of 5.08% of the Issuer’s issued and outstanding shares of common stock. As of October 4, 2023, the reporting person has a beneficial ownership of less than 5% based on the shares outstanding as reported by the Issuer’s transfer agent.

     

     
    8

     

      

    Item 1.

     

    (a)

    Name of Issuer: BioNexus Gene Lab Corp.

     

    (b)

    Address of Issuer’s Principal Executive Offices: 

    Unit 02, Level 10, Tower B, Vertical Business Suite

    Bangsar South, 8 Jalan Kerinchi

    59200 Kuala Lumpur

    Malaysia

     

    Item 2.

     

    (a)

    Name of Person Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Chan Chong Wong

    Chi Yuen Leong

    Soo Kow Lai

    Wong Kim Hai

    Tai Tan Liong

    Tham Too Kam

    Tan Kuan Yew

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    Unit 02, Level 10, Tower B, Vertical Business Suite

    Bangsar South, 8 Jalan Kerinchi

    59200 Kuala Lumpur

    Malaysia

     

     
    9

     

      

    (c)

    Citizenship:

    The citizenship of each of the Reporting Persons is:

    Malaysia

     

    (d)

    Title and Class of Securities:

    Shares of common stock

     

    (e)

    CUSIP No.:

    090628207

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4.

    Ownership

     

    The following information with respect to the ownership of the common stock of the Issuer by the Reporting Persons filing this Statement is provided as of October 4, 2023:

     

    (a) Amount beneficially owned:

     

    See Row 9 and the corresponding footnotes on the cover page for each Reporting Person.

     

    (b) Percent of Class:

     

    See Row 11 and the corresponding footnotes on the cover page for each Reporting Person.

     

    (c) Number of shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote:

     

    See Row 5 and the corresponding footnotes on the cover page for each Reporting Person.

     

    (ii) Shared power to vote or to direct the vote:

     

    See Row 6 and the corresponding footnotes on the cover page for each Reporting Person.

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    See Row 7 and the corresponding footnotes on the cover page for each Reporting Person.

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    See Row 8 and the corresponding footnotes on the cover page for each Reporting Person.

     

     
    10

     

       

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒. 

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    Not applicable

      

    Item 8.

    Identification and classification of members of the group.

     

    Not applicable

     

    Item 9.

    Notice of Dissolution of Group.

     

    Not applicable

     

    Item 10.

    Certifications.

     

    By signing below the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    11

     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 6, 2023

     

    /s/ Chan Chong Wong

     

    Chan Chong Wong

     

     

    /s/ Chi Yuen Leong

     

    Chi Yuen Leong

     

     

    /s/ Soo Kow Lai

     

    Soo Kow Lai

     

     

    /s/ Wong Kim Hai

     

    Wong Kim Hai

     

     

    /s/ Tai Tan Liong

     

    Tai Tan Liong

     

     

    /s/ Tham Too Kam

     

    Tham Too Kam

     

     

    /s/ Tan Kuan Yew

     

    Tan Kuan Yew

     

     

     
    12

      

    Get the next $BGLC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGLC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGLC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

      KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit

      4/30/25 11:25:00 AM ET
      $BGLC
      Medical Specialities
      Health Care
    • BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

      KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The Company's 2024 report showcases a year of strategic realignment, technological advancement, and enhanced corporate governance - positioning BGLC for sustainable long-term growth. Financial Resilience and Market Stability BGLC ended 2024 with a strong cash position of over $4million and total l

      4/15/25 11:00:17 AM ET
      $BGLC
      Medical Specialities
      Health Care
    • BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy

      KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC's Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation. Through this partnership, BGLC plans to leverage ML Tech's cutting-edge digital asset trading infrastru

      3/7/25 11:00:10 AM ET
      $BGLC
      Medical Specialities
      Health Care

    $BGLC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Wong Yee Meng

      3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

      10/4/23 3:57:35 PM ET
      $BGLC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Yap Chee Keong

      3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

      10/4/23 3:57:20 PM ET
      $BGLC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Yew Chak Hua

      3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

      10/4/23 3:57:07 PM ET
      $BGLC
      Medical Specialities
      Health Care

    $BGLC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioNexus Gene Lab Corp

      SC 13G - BioNexus Gene Lab Corp (0001737523) (Subject)

      10/17/23 11:46:33 AM ET
      $BGLC
      Medical Specialities
      Health Care

    $BGLC
    Leadership Updates

    Live Leadership Updates

    See more
    • BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

      KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit

      4/30/25 11:25:00 AM ET
      $BGLC
      Medical Specialities
      Health Care

    $BGLC
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioNexus Gene Lab Corp

      10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)

      5/15/25 4:30:39 PM ET
      $BGLC
      Medical Specialities
      Health Care
    • BioNexus Gene Lab Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

      4/30/25 11:16:20 AM ET
      $BGLC
      Medical Specialities
      Health Care
    • Amendment: SEC Form 10-K/A filed by BioNexus Gene Lab Corp

      10-K/A - BioNexus Gene Lab Corp (0001737523) (Filer)

      4/29/25 3:22:15 PM ET
      $BGLC
      Medical Specialities
      Health Care